Antibodies that bind to c-Met and uses thereof
Single variable domain antibodies targeting c-Met provide a novel approach to inhibit HGF/c-Met signaling, effectively blocking tumor growth and proliferation by enhancing the therapeutic arsenal against cancers with aberrant c-Met expression.
Patent Information
- Application Number
- JP2024523760
- Authority / Receiving Office
- JP · JP
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2021-11-05
- Filing Date
- 2022-11-04
- Publication Date
- 2024-11-13
AI Technical Summary
Current immunotherapeutic agents targeting c-Met, a receptor tyrosine kinase involved in tumor growth and progression, are limited in availability and effectiveness, necessitating the development of more diverse and potent antibodies to inhibit the HGF/c-Met signaling pathway in various cancers.
Development of single variable domain antibodies or antigen-binding fragments, particularly from camelids, which can specifically bind to c-Met with high affinity and inhibit its signaling, including fusion proteins and pharmaceutical compositions for therapeutic use.
These antibodies effectively block HGF binding to c-Met, inhibit c-Met phosphorylation, and demonstrate therapeutic potential in treating tumors by inhibiting tumor cell growth and proliferation, offering diverse formats for targeted cancer therapy.
Smart Images

Figure 2024541882000001_ABST
Abstract
Description
[Technical field]
[0001] The present disclosure relates to the technical field of molecular biology, and in particular to antibodies or antigen-binding fragments thereof that bind to c-Met, and uses thereof. [Background technology]
[0002] c-Mesenchymal-epithelial transition factor (c-Met) is a receptor tyrosine kinase, and is a heterodimer of approximately 190 kDa formed by the linkage of a 50 kDa extracellular chain (α chain) and a 145 kDa transmembrane chain (β chain). The transmembrane chain (β chain) contains a SEMA domain (sema homology region, SEMA), a PSI domain (plexin semaphorin-integrin, PSI), four immunoglobulin-like repeat domains (immunoglobulin-like regions in plexins and transcription factors, IPT), a transmembrane domain, a juxtamembrane domain (JM), a tyrosine kinase domain (TK), and a C-terminal tail region (carboxyl terminus, CT). c-Met is a receptor expressed on the cell surface, and the SEMA domain is one of the important elements for ligand binding and is thought to be the binding site for its ligand, hepatocyte growth factor (HGF). HGF is synthesized by mesenchymal cells, fibroblasts, and smooth muscle cells, and exerts its biological functions by activating the HGF / c-Met signaling via a paracrine mechanism.
[0003] In various tumors, due to overexpression of c-Met and HGF, and the paracrine and autocrine positive feedback loop formed by HGF and c-Met, the HGF / c-Met signaling pathway is abnormally activated, promoting tumor cell proliferation, invasion, migration, and angiogenesis. Abnormal expression of the c-Met gene exists in many types of cancer, such as brain malignancies, breast cancer, colorectal cancer, gastric cancer, head and neck cancer, lung cancer, and liver cancer. Immunotherapeutic agents, such as antibodies, that bind to c-Met can inhibit the binding of HGF to c-Met. As c-Met is a potential therapeutic target, several c-Met-targeting antibodies have been developed, but are still limited. More available options are needed.
[0004] IgG antibodies in the Camelidae family include the conventional IgG1 with four-chain structure as well as the naturally occurring IgG2 and IgG3 heavy chain antibodies (HcAbs) that do not contain light chains. H H) can specifically bind to an antigen and have a relatively high affinity for the antigen. Based on their uniqueness, V H H domains have important advantages over conventional antibody fragments (e.g., scFv and Fab): for example, only one domain is required to specifically bind an antigen with high affinity; they can be easily converted into multivalent and multispecific formats; H H domains are highly soluble and do not tend to aggregate; V H The H molecule is small and therefore has relatively high tissue penetration; H H does not need to be paired with a light chain and therefore there is no problem of mismatching of light and heavy chains for the formation of bispecific or multispecific antibodies. [Prior art documents] [Non-patent literature]
[0005] [Non-Patent Document 1] Kabat et al., Sequences of Proteins of Immunological Interest, 5th ed., Public Health Service, National Institutes of Health, Bethesda, Md. (1991). [Non-Patent Document 2] Remington's Pharmaceutical Sciences, 18th edition, Mack Printing Company, 1990, pp. 1289-1329. [Non-Patent Document 3] Comput. Appl. Biosci., 4: 11-17 (1988) [Non-Patent Document 4] J. Mol. Biol., 484 453 (1970) Summary of the Invention [Means for solving the problem]
[0006] The present disclosure provides single variable domains, antibodies or antigen-binding fragments thereof, or fusion proteins that bind to c-Met. The present disclosure also provides nucleic acids encoding the provided single variable domains, antibodies or antigen-binding fragments thereof, or fusion proteins, vectors, cells, methods of preparation, compositions, and uses.
[0007] In one aspect, the disclosure provides an isolated single variable domain that binds to c-Met, wherein the single variable domain comprises a CDR1, CDR2, and CDR3 in the amino acid sequence set forth in SEQ ID NO: 24, 26, 28, 30, 32, or 34.
[0008] In one aspect, the disclosure provides an isolated single variable domain that binds to c-Met, wherein the single variable domain comprises the following complementarity determining regions: (a) a CDR1 comprising the amino acid sequence set forth in SEQ ID NO: 5, 8, 11, 14, 17, or 20; (b) a CDR2 comprising the amino acid sequence set forth in SEQ ID NO: 6, 9, 12, 15, 18, or 21; and (c) a CDR3 comprising the amino acid sequence set forth in SEQ ID NO: 7, 10, 13, 16, 19, or 22.
[0009] In one aspect, the disclosure provides an isolated antibody or antigen-binding fragment thereof that binds to c-Met, wherein the antibody or antigen-binding fragment thereof comprises a single variable domain, the single variable domain comprising CDR1, CDR2, and CDR3 in the amino acid sequence set forth in SEQ ID NO: 24, 26, 28, 30, 32, or 34.
[0010] In one aspect, the disclosure provides an isolated antibody or antigen-binding fragment thereof that binds to c-Met, wherein the antibody or antigen-binding fragment thereof comprises a single variable domain, the single variable domain comprising the following complementarity determining regions: (a) a CDR1 comprising the amino acid sequence set forth in SEQ ID NO:5, 8, 11, 14, 17, or 20; (b) a CDR2 comprising the amino acid sequence set forth in SEQ ID NO:6, 9, 12, 15, 18, or 21; and (c) a CDR3 comprising the amino acid sequence set forth in SEQ ID NO:7, 10, 13, 16, 19, or 22.
[0011] In one aspect, the disclosure provides an isolated antibody or antigen-binding fragment thereof that binds to c-Met, wherein the antibody or antigen-binding fragment thereof comprises a single variable domain, and the single variable domain binds to the same epitope as any one of the single variable domains of the disclosure.
[0012] In one aspect, the disclosure provides an isolated antibody or antigen-binding fragment thereof that binds to c-Met, wherein the antibody or antigen-binding fragment thereof comprises a single variable domain, and the single variable domain competes with any one of the single variable domains of the disclosure for binding to c-Met.
[0013] In some embodiments, the single variable domain is H H, preferably Camelidae V H H or humanized V H It's H.
[0014] In some embodiments, the antibody or antigen-binding fragment thereof is chimeric or humanized, hi some embodiments, the single variable domain is camelid-derived or humanized.
[0015] In some embodiments, the antibody or antigen-binding fragment thereof comprises an IgG Fc. In some embodiments, the antibody or antigen-binding fragment thereof comprises a human IgG Fc, preferably a human IgG1, IgG2, IgG3, or IgG4 Fc.
[0016] In one aspect, the disclosure provides a fusion protein comprising an antibody or antigen-binding fragment thereof of the disclosure.
[0017] In one aspect, the disclosure provides a pharmaceutical composition comprising an antibody or antigen-binding fragment thereof of the disclosure and a pharma- ceutically acceptable carrier.
[0018] In one aspect, the disclosure provides an isolated nucleic acid encoding an antibody or antigen-binding fragment thereof of the disclosure.
[0019] In one aspect, the disclosure provides a vector comprising an isolated nucleic acid of the disclosure.
[0020] In one aspect, the disclosure provides a host cell comprising an isolated nucleic acid or vector of the disclosure.
[0021] In one aspect, the disclosure provides a method for preparing an antibody or antigen-binding fragment thereof of the disclosure, comprising culturing a host cell of the disclosure and isolating the expressed antibody or antigen-binding fragment thereof, wherein the vector is an expression vector.
[0022] In another aspect, the present disclosure provides use of an antibody or antigen-binding fragment thereof of the present disclosure for preparing a medicament for treating a subject having a tumor.
[0023] In another aspect, the present disclosure provides a use of a fusion protein of the present disclosure for preparing a medicament for treating a subject having a tumor.
[0024] In another aspect, the present disclosure provides a use of a pharmaceutical composition of the present disclosure for preparing a medicament for treating a subject having a tumor.
[0025] In another aspect, the disclosure provides a method for detecting or measuring c-Met in a sample, the method comprising contacting the sample with an antibody or antigen-binding fragment thereof of the disclosure and detecting or measuring the binding complex.
[0026] In another aspect, the disclosure provides a method for inhibiting, reducing or blocking c-Met signaling in a cell, the method comprising administering to the cell an effective amount of an antibody or antigen-binding fragment thereof, fusion protein, or pharmaceutical composition of the disclosure.
[0027] In another aspect, the disclosure provides a method for inhibiting the proliferation or killing of a tumor cell, the method comprising administering to the tumor cell an effective amount of an antibody or antigen-binding fragment thereof, fusion protein, or pharmaceutical composition of the disclosure.
[0028] In another aspect, the present disclosure provides a method for treating a subject having a tumor, the method comprising administering to the subject a therapeutically effective amount of an antibody or antigen-binding fragment thereof, fusion protein, or pharmaceutical composition of the present disclosure. [Brief description of the drawings]
[0029] [Figure 1A] 1 shows flow cytometry assay curves for binding of anti-human c-Met VHH-Fc chimeric antibodies to H1993 cells. [Figure 1B] 1 shows flow cytometry assay curves for binding of anti-human c-Met VHH-Fc chimeric antibody to MKN45 cells. [Figure 1C] 1 shows flow cytometry assay curves for binding of anti-human c-Met VHH-Fc chimeric antibody to KP4 cells. [Figure 1D] 1 shows flow cytometry assay curves for binding of anti-human c-Met VHH-Fc chimeric antibody to 4MBr-5 cells. [Figure 2A] 1 shows the results of a competitive ELISA assay regarding the blocking effect of an anti-human c-Met VHH-Fc chimeric antibody on the binding of HGF to c-Met. [Figure 2B] 1 shows the results of a competitive ELISA assay regarding the blocking effect of an anti-human c-Met VHH-Fc chimeric antibody on the binding of HGFβ to c-Met. [Diagram 3] 1 shows the results of an assay of the inhibitory effect of an anti-human c-Met VHH-Fc chimeric antibody on c-Met phosphorylation stimulated by HGF in H441 cells. [Figure 4] 1 shows the results of a CCK8 assay for inhibition of KP4 cell proliferation by anti-human c-Met VHH-Fc chimeric antibodies. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
[0030] definition Unless otherwise stated, the following terms used in this disclosure shall have the following meanings: Certain terms, unless specifically defined otherwise, should not be considered vague or indefinite and should be interpreted according to their ordinary meaning in the art.
[0031] The term "antibody" is used in its broadest sense and encompasses a variety of antibody structures, including, but not limited to, monoclonal antibodies, polyclonal antibodies, and multispecific antibodies (e.g., bispecific or trispecific antibodies), so long as they exhibit the desired antigen-binding activity.
[0032] The term "antigen-binding fragment" includes Fab, Fab', F(ab')2, scFv, Fv, Fd, Fd', single variable domains (e.g., V H H), and other antibody fragments known in the art, which retain the antigen-binding function of the full-length antibody, or modified fragments based on the above fragments with any modification known in the art.
[0033] The term "variable domain" or "variable region" refers to the domain of an antibody that is involved in binding the antibody to an antigen. Each variable domain of a natural antibody essentially consists of four framework regions and three complementarity determining regions. The four "framework regions" are referred to in the art and herein as "framework region 1" or "FR1", "framework region 2" or "FR2", "framework region 3" or "FR3", and "framework region 4" or "FR4". The framework regions are separated by three complementarity determining regions CDRs, referred to in the art and herein as "complementarity determining region 1" or "CDR1", "complementarity determining region 2" or "CDR2", and "complementarity determining region 3" or "CDR3". Thus, the general structure or sequence of a variable domain can be represented as follows: FR1-CDR1-FR2-CDR2-FR3-CDR3-FR4. The variable domain contains the antigen binding site, thereby conferring specificity to the antibody for the antigen.
[0034] The term "single variable domain" refers to having a variable domain that can specifically bind to an antigen epitope without pairing with another variable domain. The antigen-binding site of a single variable domain is typically formed from three CDRs (CDR1, CDR2, and CDR3) and is present on a single domain. In some cases, a single variable domain may be a heavy chain variable domain (e.g., a V chain variable domain) as long as it can form a single antigen-binding unit (i.e., a functional antigen-binding unit essentially consisting of a single variable domain; in this way, a single antigen-binding domain can form a functional antigen-binding unit without interacting with another variable domain).H ) or a suitable fragment thereof. Another example of a single variable domain is the "V H This is the VHH domain, V H Also known as H or VHH.
[0035] "V H The term H domain refers to these variable domains as heavy chain variable domains (heavy chain variable domains, herein referred to as "VH domains") present in conventional four-chain antibodies. H Domain" or "V H ") and the light chain variable domain present in conventional four-chain antibodies (referred to herein as "V L Domain" or "V L This is used to distinguish it from the "V H The H domain specifically binds to the epitope without the involvement of additional antigen-binding domains (this is the case for the V domain of a conventional four-chain antibody). H Or V L Unlike the domain, in this case the epitope is L and V H domain). H The H domain is a small, stable and efficient antigen recognition unit formed from a single domain.
[0036] The term "framework region" (FR) residues refers to amino acid residues of the variable domain other than the CDR residues as herein defined.
[0037] "Complementarity determining regions" (CDRs) are also called "hypervariable regions (HVRs)". Naturally occurring four-chain antibodies typically contain six CDRs, three in the heavy chain variable region (heavy chain CDR1, heavy chain CDR2, and heavy chain CDR3) and three in the light chain variable region (light chain CDR1, light chain CDR2, and light chain CDR3). Heavy chain antibodies or single variable domains typically have three CDRs (CDR1, CDR2, and CDR3). CDR3 is the most diverse of the three CDRs and is believed to play a unique role in conferring fine specificity to antibodies.
[0038] Currently, there are many methods for defining CDRs. The Kabat scheme defines CDRs based on sequence variability and is the most commonly used (Elvin A. Kabat et al., Sequences of Proteins of Immunological Interest, 5th ed., Public Health Service, National Institutes of Health, Bethesda, Md. (1991)), while the Chothia scheme defines CDRs based on the location of structural loops (Cyrus Chothia et al., Canonical Structures for the Hypervariable Regions of Immunoglobulins, J. Mol. Biol, 196: 901-917 (1987)). The AbM scheme, a compromise between the Kabat and Chothia schemes, is used by Oxford Molecular's AbM antibody modeling software. "Contact" defines CDRs based on analysis of available complex crystal structures. However, it should be noted that the boundaries of the CDRs of the variable regions of the same antibody based on different methods and definitions may be different, i.e., the CDR sequences of the variable regions of the same antibody defined by different methods may be different. Thus, when referring to an antibody defined with a particular CDR sequence as defined herein, the scope of the antibody also includes antibodies defined by CDR sequences converted to any other definition (e.g., a combination of one or more of the IMGT, Chothia, AbM definitions, etc.).
[0039] The term "human consensus framework" or "acceptor human framework" refers to the human immunoglobulin V L Or V H The most frequently occurring amino acid residues in the framework sequence are selected. Generally, the framework of human immunoglobulin V L Or V HThe sequences are selected from a subgroup of variable domain sequences. Typically, the subgroup of sequences are those described in Kabat et al., Sequences of Proteins of Immunological Interest, 5th ed., Public Health Service, National Institutes of Health, Bethesda, Md. (1991). Examples include: L For V, the subgroup can be subgroup κI, κII, κIII or κIV as described by Kabat et al. (from the same source as above). H For the human consensus framework regions, the subgroup can be subgroup I, subgroup II, or subgroup III as described by Kabat et al. Alternatively, the human consensus framework regions may be derived from the specific residues listed above, e.g., where the human framework residues are selected according to their homology to the donor framework regions by aligning the donor framework region sequences with a set of different human framework region sequences, the acceptor human framework "derived from" the human consensus framework region may comprise the same amino acid sequence or may comprise pre-existing amino acid sequence diversity. In some embodiments, the number of pre-existing amino acid changes is 10 or less, 9 or less, 8 or less, 7 or less, 6 or less, 5 or less, 4 or less, 3 or less, or 2 or less.
[0040] The term "Fc domain" or "Fc" is used to define the C-terminal region of an immunoglobulin heavy chain that contains at least a portion of the constant region. This term includes native sequence Fc and variant Fc. The C-terminal lysine of Fc (Lys447 according to the EU numbering system) may or may not be present.
[0041] EC 50The term "IC" refers to the effective concentration of a particular compound (e.g., an antibody or antigen-binding fragment thereof) that is 50% of the maximum molecular response. 50 The term EC refers to the inhibitory concentration that is 50% of the maximum molecular response of a compound (e.g., an antibody or antigen-binding fragment thereof). 50 and IC 50 Both can be measured by ELISA or FACS assay, or any other method known in the art.
[0042] "K a The term "K" or "association rate constant" refers to the association rate constant of molecules of a particular compound (e.g., an antibody or antigen-binding fragment thereof) that binds to an antigen to form a complex. d The term "K" or "dissociation rate constant" refers to the dissociation rate constant for the dissociation of a molecule of a particular compound (e.g., an antibody or antigen-binding fragment thereof) from a complex. D " or "equilibrium dissociation constant" refers to the dissociation rate constant (K d ) to the association rate constant (K a The binding affinity between a molecule of a particular compound and an antigen is expressed as K a , K d , and K D It is expressed using the K a , K d , and K D Methods for determining the value of are well known in the art.
[0043] The term "pharmaceutically acceptable" refers to a substance, e.g., a carrier or diluent, that does not destroy the biological activity or properties of the compounds described herein. Such a substance may be administered to an individual without causing undesired biological effects or interacting in a deleterious manner with any of the components of the composition in which it is contained.
[0044] The term "pharmaceutical acceptable carrier" includes any and all solvents, dispersion media, coating materials, surfactants, antioxidants, preservatives (e.g., antibacterial and antifungal agents), isotonicity agents, absorption retardants, salts, preservatives, drug stabilizers, binders, excipients, disintegrants, lubricants, sweeteners, flavoring agents, dyes, and the like, and combinations thereof, as are well known to those skilled in the art (Remington's Pharmaceutical Sciences, 18th Edition, Mack Printing Company, 1990, pp. 1289-1329). The use of any conventional carrier in therapeutic or pharmaceutical compositions is contemplated, unless it is incompatible with the active ingredient.
[0045] The term "treating" or "treatment" refers to an attempt to modify the natural course of a disease in a treated individual, which may be a clinical intervention performed for prophylaxis or during the course of clinical pathology. Desired therapeutic effects include, but are not limited to, preventing the onset or recurrence of a disease, alleviating symptoms, reducing any direct or indirect pathological consequences of a disease, preventing metastasis, slowing the rate of disease progression, improving or alleviating the disease state, and regressing or improving prognosis.
[0046] As used herein, the term "therapeutically effective amount" refers to the amount of a compound, pharmaceutical composition, or pharmaceutical combination required to provide a therapeutic benefit to a subject.
[0047] The term "subject" includes any human or non-human animal. The term "non-human animal" includes all vertebrates, e.g., mammals and non-mammals, e.g., non-human primates, sheep, dogs, cats, horses, cows, chickens, amphibians, and reptiles. Preferably, a subject according to the present disclosure is a human. The terms "patient" and "subject" are used interchangeably unless otherwise indicated.
[0048] The terms "specific binding" or "specifically binds" mean that the binding is selective for the antigen and can be distinguished from interactions that are undesired or non-specific. The ability of a molecule of a particular compound (e.g., an antibody or an antigen-binding fragment thereof) to bind to a particular antigenic determinant can be measured by enzyme-linked immunosorbent assay (ELISA) or other techniques well known to those skilled in the art, such as surface plasmon resonance (SPR) techniques (analysis on a Biacore instrument).
[0049] The term "isolated" refers to a compound that is isolated from a target compound, e.g., an antibody or an antigen-binding fragment thereof, H H, or the nucleic acid has been isolated from its natural environment.
[0050] The term sequence "identity" is also known as consistency. The percent identity between two sequences is a function of the identical positions shared by the sequences (i.e., percent identity=number of identical positions / total number of positions×100), where the number of gaps and the length of each gap that need to be introduced to produce optimal alignment of the two sequences should be taken into account. As shown in the non-limiting examples below, comparison of sequences and determination of percent identity between two sequences can be accomplished using a mathematical algorithm. The percent identity between two amino acid sequences can be determined using the algorithm of E. Meyers and W. Miller (Comput. Appl. Biosci., 4: 11-17 (1988)), which is incorporated into the ALIGN program (version 2.0), using a PAM120 residue weight table with a gap length penalty of 12 and a gap penalty of 4. Furthermore, the percent identity of two amino acid sequences can be determined using the algorithm of Needleman and Wunsch (J. Mol. Biol., 484 453 (1970)), which is incorporated into the GAP program in the GCG software package (available at www.gcg.com), using a Blossum 62 matrix or a PAM250 matrix, with gap weights of 16, 14, 12, 10, 8, 6 or 4, and length weights of 1, 2, 3, 4, 5 or 6.
[0051] As used herein, "about" means within an acceptable error range as determined by one of ordinary skill in the art for a particular value, which depends in part on how the value is measured or determined, i.e., the limitations of the measurement system. For example, "about" may mean within one or more standard deviations, as is customarily done in the art. Alternatively, about may mean varying within a given numerical range of up to 20% (i.e., ±20%), e.g., ±10%, ±5%, ±2%, ±1%, or ±0.5%. Furthermore, particularly with respect to biological systems or methods, the term may mean up to an order of magnitude, or up to 5-fold, of a particular value. When a particular value is given in this disclosure or claims, unless otherwise indicated, "about" should be considered to mean within an acceptable error range for that particular value.
[0052] Amino acid residues in proteins are abbreviated as follows: phenylalanine is Phe or F, leucine is Leu or L, isoleucine is Ile or I, methionine is Met or M, valine is Val or V, serine is Ser or S, proline is Pro or P, threonine is Thr or T, alanine is Ala or A, tyrosine is Tyr or Y, histidine is His or H, glutamine is Gln or Q, asparagine is Asn or N, lysine is Lys or K, aspartic acid is Asp or D, glutamic acid is Glu or E, cysteine is Cys or C, tryptophan is Trp or W, arginine is Arg or R, and glycine is Gly or G.
[0053] Various aspects of the disclosure are described in further detail in the following sections.
[0054] Single variable domains The present disclosure provides isolated single variable domains that bind to c-Met (e.g., human c-Met). The single variable domains provide more available options for drug development or drug construction targeting c-Met. The single variable domains have several desirable therapeutic properties, such as one or more of good affinity for human c-Met, ability to block the binding of the ligand HGF or its β-chain to c-Met, and inhibition of c-Met phosphorylation caused by HGF stimulation.
[0055] In some embodiments, the single variable domain binds to a c-Met that comprises one, two or all three CDRs of the variable region sequence set forth in SEQ ID NO:24. In one particular embodiment, the single variable domain binds to a c-Met that comprises the CDR1, CDR2 and CDR3 of the variable region sequence set forth in SEQ ID NO:24. In some embodiments, the single variable domain binds to a c-Met that comprises one, two or all three CDRs of the variable region sequence set forth in SEQ ID NO:26. In one particular embodiment, the single variable domain binds to a c-Met that comprises the CDR1, CDR2 and CDR3 of the variable region sequence set forth in SEQ ID NO:26. In some embodiments, the single variable domain binds to a c-Met that comprises one, two or all three CDRs of the variable region sequence set forth in SEQ ID NO:28. In one particular embodiment, the single variable domain binds to a c-Met that comprises the CDR1, CDR2 and CDR3 of the variable region sequence set forth in SEQ ID NO:28. In some embodiments, the single variable domain binds to a c-Met that comprises one, two or all three CDRs of the variable region sequence set forth in SEQ ID NO: 30. In one particular embodiment, the single variable domain binds to a c-Met that comprises the CDR1, CDR2 and CDR3 of the variable region sequence set forth in SEQ ID NO: 30. In some embodiments, the single variable domain binds to a c-Met that comprises one, two or all three CDRs of the variable region sequence set forth in SEQ ID NO: 32. In one particular embodiment, the single variable domain binds to a c-Met that comprises the CDR1, CDR2 and CDR3 of the variable region sequence set forth in SEQ ID NO: 32. In some embodiments, the single variable domain binds to a c-Met that comprises one, two or all three CDRs of the variable region sequence set forth in SEQ ID NO: 34. In one particular embodiment, the single variable domain binds to a c-Met that comprises the CDR1, CDR2 and CDR3 of the variable region sequence set forth in SEQ ID NO: 34. In some embodiments, the single variable domain is derived from a camelid. In some embodiments, the single variable domain is humanized. In some embodiments, the single variable domain comprises an acceptor human framework.
[0056] In some embodiments, the single variable domain binds to c-Met comprising at least one, at least two, or all three CDRs selected from: (a) a CDR1 comprising the amino acid sequence set forth in SEQ ID NO: 5, 8, 11, 14, 17, or 20, (b) a CDR2 comprising the amino acid sequence set forth in SEQ ID NO: 6, 9, 12, 15, 18, or 21, and (c) a CDR3 comprising the amino acid sequence set forth in SEQ ID NO: 7, 10, 13, 16, 19, or 22. In some embodiments, the single variable domain binds to c-Met comprising the following complementarity determining regions: (a) a CDR1 comprising the amino acid sequence set forth in SEQ ID NO: 5, 8, 11, 14, 17, or 20, (b) a CDR2 comprising the amino acid sequence set forth in SEQ ID NO: 6, 9, 12, 15, 18, or 21, and (c) a CDR3 comprising the amino acid sequence set forth in SEQ ID NO: 7, 10, 13, 16, 19, or 22. In some embodiments, the single variable domain is derived from an animal of the Camelidae family. In some embodiments, the single variable domain is humanized, hi some embodiments, the single variable domain comprises an acceptor human framework.
[0057] In some embodiments, the single variable domain binds to a c-Met comprising a CDR1 comprising the amino acid sequence set forth in SEQ ID NO:5, a CDR2 comprising the amino acid sequence set forth in SEQ ID NO:6, and a CDR3 comprising the amino acid sequence set forth in SEQ ID NO:7. In some embodiments, the single variable domain binds to a c-Met comprising a CDR1 comprising the amino acid sequence set forth in SEQ ID NO:8, a CDR2 comprising the amino acid sequence set forth in SEQ ID NO:9, and a CDR3 comprising the amino acid sequence set forth in SEQ ID NO:10. In some embodiments, the single variable domain binds to a c-Met comprising a CDR1 comprising the amino acid sequence set forth in SEQ ID NO:11, a CDR2 comprising the amino acid sequence set forth in SEQ ID NO:12, and a CDR3 comprising the amino acid sequence set forth in SEQ ID NO:13. In some embodiments, the single variable domain binds to a c-Met comprising a CDR1 comprising the amino acid sequence set forth in SEQ ID NO:14, a CDR2 comprising the amino acid sequence set forth in SEQ ID NO:15, and a CDR3 comprising the amino acid sequence set forth in SEQ ID NO:16. In some embodiments, the single variable domain binds to c-Met comprising a CDR1 comprising the amino acid sequence set forth in SEQ ID NO: 17, a CDR2 comprising the amino acid sequence set forth in SEQ ID NO: 18, and a CDR3 comprising the amino acid sequence set forth in SEQ ID NO: 19. In some embodiments, the single variable domain binds to c-Met comprising a CDR1 comprising the amino acid sequence set forth in SEQ ID NO: 20, a CDR2 comprising the amino acid sequence set forth in SEQ ID NO: 21, and a CDR3 comprising the amino acid sequence set forth in SEQ ID NO: 22. In some embodiments, the single variable domain is derived from an animal of the Camelidae family. In some embodiments, the single variable domain is humanized. In some embodiments, the single variable domain comprises an acceptor human framework.
[0058] In some embodiments, the single variable domain binds to a c-Met comprising a CDR1 of the amino acid sequence set forth in SEQ ID NO:5, a CDR2 of the amino acid sequence set forth in SEQ ID NO:6, and a CDR3 of the amino acid sequence set forth in SEQ ID NO:7. In some embodiments, the single variable domain binds to a c-Met comprising a CDR1 of the amino acid sequence set forth in SEQ ID NO:8, a CDR2 of the amino acid sequence set forth in SEQ ID NO:9, and a CDR3 of the amino acid sequence set forth in SEQ ID NO:10. In some embodiments, the single variable domain binds to a c-Met comprising a CDR1 of the amino acid sequence set forth in SEQ ID NO:11, a CDR2 of the amino acid sequence set forth in SEQ ID NO:12, and a CDR3 of the amino acid sequence set forth in SEQ ID NO:13. In some embodiments, the single variable domain binds to a c-Met comprising a CDR1 of the amino acid sequence set forth in SEQ ID NO:14, a CDR2 of the amino acid sequence set forth in SEQ ID NO:15, and a CDR3 of the amino acid sequence set forth in SEQ ID NO:16. In some embodiments, the single variable domain binds to c-Met comprising a CDR1 of the amino acid sequence set forth in SEQ ID NO: 17, a CDR2 of the amino acid sequence set forth in SEQ ID NO: 18, and a CDR3 of the amino acid sequence set forth in SEQ ID NO: 19. In some embodiments, the single variable domain binds to c-Met comprising a CDR1 of the amino acid sequence set forth in SEQ ID NO: 20, a CDR2 of the amino acid sequence set forth in SEQ ID NO: 21, and a CDR3 of the amino acid sequence set forth in SEQ ID NO: 22. In some embodiments, the single variable domain is derived from an animal of the family Camelidae. In some embodiments, the single variable domain is humanized. In some embodiments, the single variable domain comprises an acceptor human framework.
[0059] In some embodiments, the single variable domain binds to c-Met comprising an amino acid sequence having at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity to the amino acid sequence set forth in SEQ ID NO: 24, 26, 28, 30, 32, or 34, and optionally the single variable domain comprises a specific CDR1, CDR2, and / or CDR3 sequence as set forth above.
[0060] In some embodiments, the single variable domain binds to c-Met comprising an amino acid sequence having at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity to the amino acid sequence set forth in SEQ ID NO:24, and the single variable domain comprises a CDR1 comprising the amino acid sequence set forth in SEQ ID NO:5, a CDR2 comprising the amino acid sequence set forth in SEQ ID NO:6, and a CDR3 comprising the amino acid sequence set forth in SEQ ID NO:7.
[0061] In some embodiments, the single variable domain binds to c-Met comprising an amino acid sequence having at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity to the amino acid sequence set forth in SEQ ID NO:26, and the single variable domain comprises a CDR1 comprising the amino acid sequence set forth in SEQ ID NO:8, a CDR2 comprising the amino acid sequence set forth in SEQ ID NO:9, and a CDR3 comprising the amino acid sequence set forth in SEQ ID NO:10.
[0062] In some embodiments, the single variable domain binds to c-Met comprising an amino acid sequence having at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity to the amino acid sequence set forth in SEQ ID NO:28, and the single variable domain comprises a CDR1 comprising the amino acid sequence set forth in SEQ ID NO:11, a CDR2 comprising the amino acid sequence set forth in SEQ ID NO:12, and a CDR3 comprising the amino acid sequence set forth in SEQ ID NO:13.
[0063] In some embodiments, the single variable domain binds to c-Met comprising an amino acid sequence having at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity to the amino acid sequence set forth in SEQ ID NO:30, and the single variable domain comprises a CDR1 comprising the amino acid sequence set forth in SEQ ID NO:14, a CDR2 comprising the amino acid sequence set forth in SEQ ID NO:15, and a CDR3 comprising the amino acid sequence set forth in SEQ ID NO:16.
[0064] In some embodiments, the single variable domain binds to c-Met comprising an amino acid sequence having at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity to the amino acid sequence set forth in SEQ ID NO: 32, and the single variable domain comprises a CDR1 comprising the amino acid sequence set forth in SEQ ID NO: 17, a CDR2 comprising the amino acid sequence set forth in SEQ ID NO: 18, and a CDR3 comprising the amino acid sequence set forth in SEQ ID NO: 19.
[0065] In some embodiments, the single variable domain binds to c-Met comprising an amino acid sequence having at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity to the amino acid sequence set forth in SEQ ID NO: 34, and the single variable domain comprises a CDR1 comprising the amino acid sequence set forth in SEQ ID NO: 20, a CDR2 comprising the amino acid sequence set forth in SEQ ID NO: 21, and a CDR3 comprising the amino acid sequence set forth in SEQ ID NO: 22.
[0066] In some embodiments, a single variable domain amino acid sequence having at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity contains substitutions (e.g., conservative substitutions), insertions, or deletions compared to a reference sequence, but a single variable domain comprising that sequence retains the ability to bind to c-Met. In some embodiments, a total of 1 to 18, 1 to 16, 1 to 14, 1 to 12, 1 to 10, 1 to 9, 1 to 8, 1 to 7, 1 to 6, 1 to 5, 1 to 4, 1 to 3, or 1 to 2 amino acids are substituted, inserted, and / or deleted in an amino acid sequence selected from SEQ ID NOs: 24, 26, 28, 30, 32, and 34. In some embodiments, the substitution, insertion or deletion occurs in a region outside the CDR (i.e., in the FR). In some embodiments, the substitution, insertion or deletion occurs in a CDR region, for example, in one, two or three of CDR1, CDR2 and CDR3. In some embodiments, the substitution, insertion or deletion occurs in a CDR region and in a non-CDR region. Optionally, the single variable domain comprises an amino acid sequence selected from SEQ ID NOs: 24, 26, 28, 30, 32 and 34, including post-translational modifications of the sequence.
[0067] In some embodiments, the single variable domain binds to a c-Met comprising the amino acid sequence set forth in SEQ ID NO: 24, 26, 28, 30, 32, or 34.
[0068] In some embodiments, the single variable domain (including any of the above embodiments, e.g., a single variable domain comprising a particular CDR1, CDR2 and / or CDR3) is H H. In certain embodiments, V H H has the following structure from N-terminus to C-terminus: FR1-CDR1-FR2-CDR2-FR3-CDR3-FR4.
[0069] In some embodiments, the single variable domain (including any of the above embodiments, e.g., a single variable domain comprising a particular CDR1, CDR2 and / or CDR3) is a humanized V H H. V of non-human origin H H is the original V H One or more amino acid residues in the amino acid sequence of H are replaced with V of a conventional human four-chain antibody. H It can be "humanized" by replacing one or more amino acid residues present at the corresponding positions in the domain. Humanization may be desirable to reduce immunogenicity.
[0070] In some embodiments, the single variable domain binds to c-Met, the amino acid sequence of which is set forth in SEQ ID NO: 24, 26, 28, 30, 32, or 34.
[0071] The present disclosure also provides single variable domains that bind to the same epitope as any one of the single variable domains of the present disclosure. In certain embodiments, the single variable domain binds to the same epitope as a single variable domain comprising the amino acid sequence set forth in SEQ ID NO: 24, 26, 28, 30, 32, or 34. In some embodiments, the single variable domains that bind to the same epitope are derived from a camelid or are humanized.
[0072] Competitive screening of single variable domains can be performed using conventional techniques known to those skilled in the art based on binding to the same epitope. For example, a competition test can be performed to obtain single variable domains that compete with each other for binding to an antigen. Thus, the present disclosure also provides single variable domains that compete with any one of the single variable domains described in the present disclosure for binding to c-Met. In some specific embodiments, the single variable domain competes with a single variable domain comprising the amino acid sequence set forth in SEQ ID NO: 24, 26, 28, 30, 32, or 34 for binding to c-Met. Binding to c-Met can be measured by ELISA, flow cytometry, or surface plasmon resonance (SPR) assay, or any other method known in the art. In some embodiments, the single variable domain that competes for binding to c-Met is derived from a camelid or is humanized.
[0073] In some embodiments, a single variable domain according to any one of the above embodiments may comprise one or several of the following properties and characteristics, either alone or in combination: (i) binding to human c-Met or / and monkey c-Met; (ii) blocking the binding of HGF or its β chain to c-Met; or (iii) inhibiting c-Met phosphorylation induced by HGF stimulation.
[0074] In some embodiments, the single variable domain binds to c-Met. In some embodiments, the single variable domain blocks the binding of HGF or its β chain to c-Met. In some embodiments, the single variable domain inhibits c-Met phosphorylation caused by HGF stimulation.
[0075] The present disclosure provides several exemplary single variable domains that bind to c-Met. The amino acid sequences of the CDRs (CDR1, CDR2, and CDR3) of the exemplary single variable domains provided by the present disclosure are provided below in Table S1. The full length amino acid sequences of the exemplary single variable domains are provided below in Table S2.
[0076] [Table 1]
[0077] [Table 2]
[0078] Antibody or antigen-binding fragment thereof The present disclosure provides an isolated antibody, or antigen-binding fragment thereof, that binds to c-Met (e.g., human c-Met), the antibody, or antigen-binding fragment thereof, comprising at least one single variable domain(s) of the present disclosure.
[0079] The antibodies or antigen-binding fragments thereof that bind to c-Met provided by the present disclosure have several desirable therapeutic properties, such as one or more of good affinity for human c-Met, ability to block binding of the ligand HGF or its β chain to c-Met and inhibition of c-Met phosphorylation caused by HGF stimulation, good binding ability to cells with different levels of c-Met expression, and killing of tumor cells.
[0080] In some embodiments, the antibody or antigen-binding fragment thereof binds to c-Met and comprises at least one(s) single variable domain(s), where the single variable domain comprises one, two, or all three CDRs of the variable region sequence set forth in SEQ ID NO: 24. In some particular embodiments, the antibody or antigen-binding fragment thereof binds to c-Met and comprises at least one(s) single variable domain(s), where the single variable domain comprises CDR1, CDR2, and CDR3 of the variable region sequence set forth in SEQ ID NO: 24. In some embodiments, the antibody or antigen-binding fragment thereof binds to c-Met and comprises at least one(s) single variable domain(s), where the single variable domain comprises one, two, or all three CDRs of the variable region sequence set forth in SEQ ID NO: 26. In certain embodiments, the antibody or antigen-binding fragment thereof binds to c-Met and comprises at least one single variable domain(s), where the single variable domain comprises CDR1, CDR2, and CDR3 of the variable region sequence set forth in SEQ ID NO: 26. In some embodiments, the antibody or antigen-binding fragment thereof binds to c-Met and comprises at least one single variable domain(s), where the single variable domain comprises one, two, or all three CDRs of the variable region sequence set forth in SEQ ID NO: 28. In some embodiments, the antibody or antigen-binding fragment thereof binds to c-Met and comprises at least one single variable domain(s), where the single variable domain comprises CDR1, CDR2, and CDR3 of the variable region sequence set forth in SEQ ID NO: 28. In some embodiments, the antibody or antigen-binding fragment thereof binds to c-Met and comprises at least one (one or more) single variable domains, where the single variable domain comprises one, two, or all three CDRs of the variable region sequence set forth in SEQ ID NO: 30. In some particular embodiments, the antibody or antigen-binding fragment thereof binds to c-Met and comprises at least one (one or more) single variable domains, where the single variable domain comprises CDR1, CDR2, and CDR3 of the variable region sequence set forth in SEQ ID NO: 30.In some embodiments, the antibody or antigen-binding fragment thereof binds to c-Met and comprises at least one(s) single variable domain(s), where the single variable domain comprises one, two, or all three CDRs of the variable region sequence set forth in SEQ ID NO: 32. In some particular embodiments, the antibody or antigen-binding fragment thereof binds to c-Met and comprises at least one(s) single variable domain(s), where the single variable domain comprises CDR1, CDR2, and CDR3 of the variable region sequence set forth in SEQ ID NO: 32. In some embodiments, the antibody or antigen-binding fragment thereof binds to c-Met and comprises at least one(s) single variable domain(s), where the single variable domain comprises one, two, or all three CDRs of the variable region sequence set forth in SEQ ID NO: 34. In certain embodiments, the antibody or antigen-binding fragment thereof binds to c-Met and comprises at least one (one or more) single variable domain, wherein the single variable domain comprises CDR1, CDR2, and CDR3 of the variable region sequence set forth in SEQ ID NO: 34. In some embodiments, the single variable domain is derived from a camelid. In some embodiments, the single variable domain is humanized. In some embodiments, the single variable domain comprises an acceptor human framework.
[0081] In some embodiments, the antibody or antigen-binding fragment thereof binds to c-Met and comprises at least one (one or more) single variable domain, where the single variable domain comprises at least one, at least two, or all three CDRs selected from: (a) a CDR1 comprising the amino acid sequence set forth in SEQ ID NO: 5, 8, 11, 14, 17, or 20; (b) a CDR2 comprising the amino acid sequence set forth in SEQ ID NO: 6, 9, 12, 15, 18, or 21; and (c) a CDR3 comprising the amino acid sequence set forth in SEQ ID NO: 7, 10, 13, 16, 19, or 22. In some embodiments, the antibody or antigen-binding fragment thereof binds to c-Met and comprises at least one (one or more) single variable domain, wherein the single variable domain comprises the following complementarity determining regions: (a) CDR1 comprising the amino acid sequence set forth in SEQ ID NO: 5, 8, 11, 14, 17, or 20, (b) CDR2 comprising the amino acid sequence set forth in SEQ ID NO: 6, 9, 12, 15, 18, or 21, and (c) CDR3 comprising the amino acid sequence set forth in SEQ ID NO: 7, 10, 13, 16, 19, or 22. In some embodiments, the single variable domain is derived from a camelid. In some embodiments, the single variable domain is humanized. In some embodiments, the single variable domain comprises an acceptor human framework.
[0082] In some embodiments, the single variable domain comprises (a) a CDR1 comprising the amino acid sequence set forth in SEQ ID NO:5, a CDR2 comprising the amino acid sequence set forth in SEQ ID NO:6, and a CDR3 comprising the amino acid sequence set forth in SEQ ID NO:7; (b) a CDR1 comprising the amino acid sequence set forth in SEQ ID NO:8, a CDR2 comprising the amino acid sequence set forth in SEQ ID NO:9, and a CDR3 comprising the amino acid sequence set forth in SEQ ID NO:10; (c) a CDR1 comprising the amino acid sequence set forth in SEQ ID NO:11, a CDR2 comprising the amino acid sequence set forth in SEQ ID NO:12, and a CDR3 comprising the amino acid sequence set forth in SEQ ID NO:13; (d) a CDR1 comprising the amino acid sequence set forth in SEQ ID NO:14, a CDR2 comprising the amino acid sequence set forth in SEQ ID NO:15, and a CDR3 comprising the amino acid sequence set forth in SEQ ID NO:16; (e) a CDR1 comprising the amino acid sequence set forth in SEQ ID NO:17, a CDR2 comprising the amino acid sequence set forth in SEQ ID NO:18, and a CDR3 comprising the amino acid sequence set forth in SEQ ID NO:19; or (f) a CDR1 comprising the amino acid sequence set forth in SEQ ID NO:20, a CDR2 comprising the amino acid sequence set forth in SEQ ID NO:21, and a CDR3 comprising the amino acid sequence set forth in SEQ ID NO:22. In some embodiments, the single variable domain is derived from a camelid. In some embodiments, the single variable domain is humanized. In some embodiments, the single variable domain comprises an acceptor human framework.
[0083] In some embodiments, the single variable domain comprises (a) a CDR1 having the amino acid sequence set forth in SEQ ID NO:5, a CDR2 having the amino acid sequence set forth in SEQ ID NO:6, and a CDR3 having the amino acid sequence set forth in SEQ ID NO:7; (b) a CDR1 having the amino acid sequence set forth in SEQ ID NO:8, a CDR2 having the amino acid sequence set forth in SEQ ID NO:9, and a CDR3 having the amino acid sequence set forth in SEQ ID NO:10; (c) a CDR1 having the amino acid sequence set forth in SEQ ID NO:11, a CDR2 having the amino acid sequence set forth in SEQ ID NO:12, and a CDR3 having the amino acid sequence set forth in SEQ ID NO:13; (d) a CDR1 having the amino acid sequence set forth in SEQ ID NO:14, a CDR2 having the amino acid sequence set forth in SEQ ID NO:15, and a CDR3 having the amino acid sequence set forth in SEQ ID NO:16; (e) a CDR1 having the amino acid sequence set forth in SEQ ID NO:17, a CDR2 having the amino acid sequence set forth in SEQ ID NO:18, and a CDR3 having the amino acid sequence set forth in SEQ ID NO:19; or (f) a CDR1 having the amino acid sequence set forth in SEQ ID NO:20, a CDR2 having the amino acid sequence set forth in SEQ ID NO:21, and a CDR3 having the amino acid sequence set forth in SEQ ID NO:22. In some embodiments, the single variable domain is derived from a camelid. In some embodiments, the single variable domain is humanized. In some embodiments, the single variable domain comprises an acceptor human framework.
[0084] In some embodiments, the single variable domain comprises an amino acid sequence having at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% identity to the amino acid sequence set forth in SEQ ID NO: 24, 26, 28, 30, 32 or 34. In some embodiments, the single variable domain comprises an amino acid sequence having at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% identity to the amino acid sequence set forth in SEQ ID NO: 24, 26, 28, 30, 32 or 34, and the single variable domain comprises a specific CDR1, CDR2 and / or CDR3 sequence as set forth above.
[0085] In some embodiments, the single variable domain comprises an amino acid sequence having at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity to the amino acid sequence set forth in SEQ ID NO:24, and the single variable domain comprises a CDR1 comprising the amino acid sequence set forth in SEQ ID NO:5, a CDR2 comprising the amino acid sequence set forth in SEQ ID NO:6, and a CDR3 comprising the amino acid sequence set forth in SEQ ID NO:7.
[0086] In some embodiments, the single variable domain comprises an amino acid sequence having at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity to the amino acid sequence set forth in SEQ ID NO:26, and the single variable domain comprises a CDR1 comprising the amino acid sequence set forth in SEQ ID NO:8, a CDR2 comprising the amino acid sequence set forth in SEQ ID NO:9, and a CDR3 comprising the amino acid sequence set forth in SEQ ID NO:10.
[0087] In some embodiments, the single variable domain comprises an amino acid sequence having at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity to the amino acid sequence set forth in SEQ ID NO:28, and the single variable domain comprises a CDR1 comprising the amino acid sequence set forth in SEQ ID NO:11, a CDR2 comprising the amino acid sequence set forth in SEQ ID NO:12, and a CDR3 comprising the amino acid sequence set forth in SEQ ID NO:13.
[0088] In some embodiments, the single variable domain comprises an amino acid sequence having at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity to the amino acid sequence set forth in SEQ ID NO: 30, and the single variable domain comprises a CDR1 comprising the amino acid sequence set forth in SEQ ID NO: 14, a CDR2 comprising the amino acid sequence set forth in SEQ ID NO: 15, and a CDR3 comprising the amino acid sequence set forth in SEQ ID NO: 16.
[0089] In some embodiments, the single variable domain comprises an amino acid sequence having at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity to the amino acid sequence set forth in SEQ ID NO: 32, and the single variable domain comprises a CDR1 comprising the amino acid sequence set forth in SEQ ID NO: 17, a CDR2 comprising the amino acid sequence set forth in SEQ ID NO: 18, and a CDR3 comprising the amino acid sequence set forth in SEQ ID NO: 19.
[0090] In some embodiments, the single variable domain comprises an amino acid sequence having at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity to the amino acid sequence set forth in SEQ ID NO: 34, and the single variable domain comprises a CDR1 comprising the amino acid sequence set forth in SEQ ID NO: 20, a CDR2 comprising the amino acid sequence set forth in SEQ ID NO: 21, and a CDR3 comprising the amino acid sequence set forth in SEQ ID NO: 22.
[0091] In some embodiments, a single variable domain amino acid sequence having at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity contains substitutions (e.g., conservative substitutions), insertions, or deletions compared to a reference sequence, but an antibody or antigen-binding fragment thereof comprising a single variable domain comprising that sequence retains the ability to bind to c-Met. In some embodiments, a total of 1 to 18, 1 to 16, 1 to 14, 1 to 12, 1 to 10, 1 to 9, 1 to 8, 1 to 7, 1 to 6, 1 to 5, 1 to 4, 1 to 3, or 1 to 2 amino acids are substituted, inserted, and / or deleted in an amino acid sequence selected from SEQ ID NOs: 24, 26, 28, 30, 32, and 34. In some embodiments, the substitution, insertion or deletion occurs in a region outside the CDR (i.e., in the FR). In some embodiments, the substitution, insertion or deletion occurs in a CDR region, for example, in one, two or three of CDR1, CDR2 and CDR3. In some embodiments, the substitution, insertion or deletion occurs in a CDR region and in a non-CDR region. Optionally, the single variable domain comprises an amino acid sequence selected from SEQ ID NOs: 24, 26, 28, 30, 32 and 34, including post-translational modifications of the sequence.
[0092] In some embodiments, the single variable domain comprises the amino acid sequence set forth in SEQ ID NO: 24, 26, 28, 30, 32, or 34.
[0093] When an antibody or antigen-binding fragment thereof comprises two or more single variable domains, the single variable domains can be selected to be the same or different. The antibody can be a monoclonal antibody, a polyclonal antibody, a multispecific antibody (e.g., a bispecific antibody or a trispecific antibody), or an antibody of other configurations known in the art. The antigen-binding fragment can be a single variable domain. In a particular embodiment, the antibody is a monospecific antibody. In a particular embodiment, the antibody is a bispecific antibody.
[0094] In some embodiments, the single variable domain (including any of the above embodiments, e.g., a single variable domain comprising a particular CDR1, CDR2 and / or CDR3) is H H. In certain embodiments, V H H has the following structure from N-terminus to C-terminus: FR1-CDR1-FR2-CDR2-FR3-CDR3-FR4.
[0095] In some embodiments, the single variable domain (including any of the above embodiments, e.g., a single variable domain comprising a particular CDR1, CDR2 and / or CDR3) is a humanized V H H. V of non-human origin H H is the original V H One or more amino acid residues in the amino acid sequence of H are replaced with V of a conventional human four-chain antibody. H It can be "humanized" by replacing one or more amino acid residues present at the corresponding positions in the domain. Humanization may be desirable to reduce immunogenicity.
[0096] In some embodiments, the antibody or antigen-binding fragment thereof is derived from a camelid. In some embodiments, the antibody or antigen-binding fragment thereof is chimeric. In some embodiments, the antibody or antigen-binding fragment thereof comprises an IgG constant region, preferably a human IgG constant region, more preferably a human IgG1 constant region, a human IgG2 constant region, a human IgG3 constant region, or a human IgG4 constant region. In some embodiments, the antibody or antigen-binding fragment thereof comprises an Fc of an IgG. In some embodiments, the antibody or antigen-binding fragment thereof comprises an Fc of a human IgG, preferably the Fc is an Fc of a human IgG1, IgG2, IgG3, or IgG4. In some embodiments, the antibody or antigen-binding fragment thereof is humanized. In some embodiments, the antibody or antigen-binding fragment thereof comprises an acceptor human framework.
[0097] In some embodiments, the antibody or antigen-binding fragment thereof comprises an amino acid sequence having at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity to the amino acid sequence set forth in SEQ ID NO: 37, 39, 41, 43, 45, or 47. In some embodiments, the antibody or antigen-binding fragment thereof comprises an amino acid sequence having at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity to the amino acid sequence set forth in SEQ ID NO: 37, 39, 41, 43, 45, or 47, and the antibody or antigen-binding fragment thereof comprises a particular CDR1, CDR2, and / or CDR3 sequence in a single variable domain described in this disclosure. In some embodiments, the antibody or antigen-binding fragment thereof comprises an amino acid sequence set forth in SEQ ID NO: 37, 39, 41, 43, 45, or 47. In some embodiments, the antibody or antigen-binding fragment thereof comprises at least one polypeptide chain, wherein the amino acid sequence of at least one polypeptide chain is set forth in SEQ ID NO: 37, 39, 41, 43, 45, or 47. In some embodiments, the antibody or antigen-binding fragment thereof comprises two identical polypeptide chains, wherein the amino acid sequence of at least one polypeptide chain is set forth in SEQ ID NO: 37, 39, 41, 43, 45, or 47.
[0098] The present disclosure also provides an antibody or antigen-binding fragment thereof that binds to the same epitope as any one of the antibodies or antigen-binding fragments thereof of the present disclosure. In certain embodiments, the antibody or antigen-binding fragment thereof binds to the same epitope as an antibody or antigen-binding fragment thereof comprising an amino acid sequence set forth in SEQ ID NO: 37, 39, 41, 43, 45, or 47. In some embodiments, the antibody or antigen-binding fragment thereof that binds to the same epitope is derived from a camelid, is chimeric, or is humanized.
[0099] Competitive screening of antibodies or antigen-binding fragments thereof based on binding to the same epitope can be performed using conventional techniques known to those skilled in the art. For example, a competition test can be performed to obtain antibodies or antigen-binding fragments thereof that compete with each other for binding to the antigen. Thus, the present disclosure also provides an antibody or antigen-binding fragment thereof that competes with any one of the antibodies or antigen-binding fragments thereof described in the present disclosure for binding to c-Met. In some specific embodiments, the antibody or antigen-binding fragment thereof competes with an antibody or antigen-binding fragment thereof comprising an amino acid sequence set forth in SEQ ID NO: 37, 39, 41, 43, 45, or 47 for binding to c-Met. Binding to c-Met can be measured by ELISA, flow cytometry, or surface plasmon resonance (SPR) assay, or any other method known in the art. In some embodiments, the antibody or antigen-binding fragment thereof that competes for binding to c-Met is derived from a camelid, is chimeric, or is humanized.
[0100] In some embodiments, an antibody or antigen-binding fragment thereof according to any one of the above embodiments may include one or several of the following properties and characteristics, either alone or in combination: (i) binding to human c-Met and / or monkey c-Met; (ii) blocking the binding of HGF or its β chain to c-Met; (iii) inhibiting c-Met phosphorylation induced by HGF stimulation; (iv) exerting antibody-dependent cellular cytotoxicity (ADCC) effect against tumor cells.
[0101] In some embodiments, the antibody or antigen-binding fragment thereof binds to c-Met, e.g., monkey c-Met and / or human c-Met. In some embodiments, the antibody or antigen-binding fragment thereof binds to cynomolgus monkey c-Met. In some embodiments, the antibody or antigen-binding fragment thereof binds to human c-Met. In some embodiments, the antibody or antigen-binding fragment thereof has the following binding affinity (KD In some embodiments, the antibody or antigen-binding fragment thereof has the following binding affinity (K) for human c-Met: D In some embodiments, the binding affinity K of the antibody or antigen-binding fragment thereof provided by the present disclosure is about 1E-07M or less, about 1E-08M or less, about 8.25E-09M or less, about 1E-09M or less, about 2.00E-10M or less, about 1E-10M or less, or about 1E-11M or less. D is measured by Biacore.
[0102] In some embodiments, the antibody or antigen-binding fragment thereof blocks binding of HGF or its β chain to c-Met.
[0103] In some embodiments, the antibody or antigen-binding fragment thereof inhibits c-Met phosphorylation caused by HGF stimulation.
[0104] In some embodiments, the antibody or antigen-binding fragment thereof exerts an ADCC effect on the tumor cell, hi some embodiments, the tumor cell is a c-Met-expressing tumor cell.
[0105] The present disclosure provides exemplary antibodies or antigen-binding fragments thereof, e.g., monospecific antibodies, including chimeric antibodies 1B-3B11-Fc, 1B-1B6-Fc, 1B-1C7-Fc, 1B-1A8-Fc, 1B-1B2-Fc, and 3B-1C7-Fc. The single variable domains are fused to human IgG1 to form homodimers via the Fc. The amino acid sequences of the exemplary antibodies are provided in Table S3 below.
[0106] [Table 3A]
[0107] [Table 3B]
[0108] Fusion proteins The single variable domains and antibodies or antigen-binding fragments thereof of the present disclosure can be used to construct any desired fusion protein, thereby imparting to the fusion protein the property of targeted binding to c-Met, or other property possessed by the single variable domain, antibody or antigen-binding fragment thereof.Thus, the present disclosure provides isolated fusion proteins comprising at least one (one or more) of the single variable domains or antibodies or antigen-binding fragments thereof of the present disclosure.
[0109] In certain embodiments, the fusion protein comprises an exemplary CDR sequence, single variable domain sequence, or antibody sequence of the disclosure, e.g., one, two, or three CDR sequences in any of the single variable domains in Table S1, any of the single variable domain sequences in Table S2, or any of the antibody sequences in Table S3, and optionally, the fusion protein may include any modification known in the art (e.g., glycosylation or chemical modification).
[0110] When the fusion protein comprises two or more single variable domains, the single variable domains may be selected to be the same or different.
[0111] Pharmaceutical Compositions The present disclosure provides a pharmaceutical composition comprising an antibody or antigen-binding fragment thereof of the present disclosure and a pharma- ceutically acceptable carrier. The present disclosure also provides a pharmaceutical composition comprising a fusion protein of the present disclosure and a pharma- ceutically acceptable carrier. In some embodiments, any one or more of 1B-3B11-Fc, 1B-1B6-Fc, 1B-1C7-Fc, 1B-1A8-Fc, 1B-1B2-Fc, and 3B-1C7-Fc antibodies and a pharma- ceutically acceptable carrier are formed into a pharmaceutical composition.
[0112] Isolated Nucleic Acids The present disclosure provides an isolated nucleic acid encoding a single variable domain or an antibody or antigen-binding fragment thereof described in the present disclosure. The present disclosure also provides an isolated nucleic acid encoding a fusion protein described in the present disclosure. In some embodiments, the nucleic acid encodes a single variable domain, such as 1B-3B11-Fc, 1B-1B6-Fc, 1B-1C7-Fc, 1B-1A8-Fc, 1B-1B2-Fc, or 3B-1C7-Fc. In some embodiments, the nucleic acid encodes an antibody or antigen-binding fragment thereof, such as 1B-3B11-Fc, 1B-1B6-Fc, 1B-1C7-Fc, 1B-1A8-Fc, 1B-1B2-Fc, or 3B-1C7-Fc.
[0113] By way of example, the nucleic acid sequences of several single variable domains, antibodies or antigen-binding fragments thereof are listed in the sequence listing.
[0114] vector The present disclosure provides a vector comprising the isolated nucleic acid. In some embodiments, the vector is a cloning vector, and in some other embodiments, the vector is an expression vector. The expression vector is any expression vector that can express the single variable domain or antibody or antigen-binding fragment thereof described in the present disclosure, as appropriate. The expression vector is any expression vector that can express the fusion protein described in the present disclosure, as appropriate. In one specific example, the expression vector is pcDNA3.1.
[0115] host cell The present disclosure provides a host cell comprising a nucleic acid or vector described herein, the host cell being suitable for cloning or expressing a single variable domain, an antibody or antigen-binding fragment thereof. The present disclosure also provides a host cell comprising a nucleic acid or vector described herein, the host cell being suitable for cloning or expressing a fusion protein. In some embodiments, the host cell is a prokaryotic cell. In other embodiments, the host cell is a eukaryotic cell. In some embodiments, the host cell is selected from a yeast cell, a mammalian cell, and other cells suitable for preparing a single variable domain, an antibody or antigen-binding fragment thereof, or a fusion protein. The mammalian cell is, for example, a Chinese Hamster Ovary (CHO) cell or a CHO-S cell.
[0116] Methods for preparing single variable domains, antibodies or antigen-binding fragments thereof, or fusion proteins The present disclosure provides a method for preparing a single variable domain, the method comprising culturing a host cell comprising a nucleic acid encoding a single variable domain of the present disclosure, and recovering the single variable domain from the host cell or host cell medium. The present disclosure also provides a method for preparing an antibody or antigen-binding fragment thereof, the method comprising culturing a host cell comprising a nucleic acid encoding an antibody or antigen-binding fragment thereof of the present disclosure, and recovering the antibody or antigen-binding fragment thereof from the host cell or host cell medium. The present disclosure also provides a method for preparing a fusion protein, the method comprising culturing a host cell comprising a nucleic acid encoding a fusion protein of the present disclosure, and recovering the fusion protein from the host cell or host cell medium.
[0117] To produce a single variable domain, or an antibody or antigen-binding fragment thereof, a nucleic acid encoding the single variable domain, antibody or antigen-binding fragment thereof is inserted into a vector for further cloning and / or expression in a host cell. To produce a fusion protein, a nucleic acid encoding the fusion protein is inserted into a vector for further cloning and / or expression in a host cell. Nucleic acids can be obtained using various methods known in the art, such as gene splicing and chemical synthesis.
[0118] use The present disclosure provides for the use of a single variable domain, an antibody or antigen-binding fragment thereof, or a fusion protein of the present disclosure. The present disclosure also provides for the use of a pharmaceutical composition of the present disclosure.
[0119] The present disclosure provides the use of a single variable domain of the present disclosure for preparing a medicament for treating a subject having a tumor. The present disclosure also provides the use of an antibody or antigen-binding fragment thereof of the present disclosure for preparing a medicament for treating a subject having a tumor. The present disclosure also provides the use of a fusion protein of the present disclosure for preparing a medicament for treating a subject having a tumor. The present disclosure also provides the use of a pharmaceutical composition of the present disclosure for preparing a medicament for treating a subject having a tumor.
[0120] The present disclosure provides a method for detecting or measuring c-Met in a sample, the method comprising contacting the sample with a single variable domain of the present disclosure, or an antibody or antigen-binding fragment thereof, and detecting or measuring the binding complex. The present disclosure also provides a method for detecting or measuring c-Met in a sample, the method comprising contacting the sample with a fusion protein of the present disclosure, and detecting or measuring the binding complex.
[0121] The present disclosure provides a method for inhibiting, reducing or blocking c-Met signaling in a cell, comprising administering to the cell an effective amount of a single variable domain, or an antibody or antigen-binding fragment thereof, as described herein. The present disclosure also provides the use of a single variable domain, or an antibody or antigen-binding fragment thereof, as described herein, for preparing a medicament for inhibiting, reducing or blocking c-Met signaling in a cell. The present disclosure also provides a method for inhibiting, reducing or blocking c-Met signaling in a cell, comprising administering to the cell an effective amount of a fusion protein of the present disclosure. The present disclosure also provides the use of a fusion protein of the present disclosure for preparing a medicament for inhibiting, reducing or blocking c-Met signaling in a cell. The present disclosure provides a method for inhibiting, reducing or blocking c-Met signaling in a cell, comprising administering to the cell an effective amount of a pharmaceutical composition as described herein. The present disclosure also provides the use of a pharmaceutical composition of the present disclosure for preparing a medicament for inhibiting, reducing or blocking c-Met signaling in a cell. In some embodiments, the cell is a tumor cell.
[0122] The present disclosure provides a method for inhibiting tumor cell proliferation or killing tumor cells, comprising administering to tumor cells an effective amount of a single variable domain or an antibody or antigen-binding fragment thereof of the present disclosure. The present disclosure also provides the use of a single variable domain or an antibody or antigen-binding fragment thereof to prepare a medicament for inhibiting tumor cell proliferation or killing tumor cells. The present disclosure also provides a method for inhibiting tumor cell proliferation or killing tumor cells, comprising administering to tumor cells an effective amount of a fusion protein of the present disclosure. The present disclosure also provides the use of a fusion protein to prepare a medicament for inhibiting tumor cell proliferation or killing tumor cells. The present disclosure provides a method for inhibiting tumor cell proliferation or killing tumor cells, comprising administering to tumor cells an effective amount of a pharmaceutical composition of the present disclosure. The present disclosure also provides the use of a pharmaceutical composition to prepare a medicament for inhibiting tumor cell proliferation or killing tumor cells.
[0123] The present disclosure provides a method for treating a subject having a tumor, comprising administering to the subject a therapeutically effective amount of a single variable domain or an antibody or antigen-binding fragment thereof described in this disclosure. The present disclosure also provides a method for treating a subject having a tumor, comprising administering to the subject a therapeutically effective amount of a fusion protein described in this disclosure. The present disclosure also provides a method for treating a subject having a tumor, comprising administering to the subject a therapeutically effective amount of a pharmaceutical composition described in this disclosure. Subjects in need of treatment include those who have a disease or condition, as well as those who may have a disease or condition and in which the goal is to prevent, delay or alleviate the disease or condition.
[0124] In some embodiments, the tumor is a c-Met expressing tumor. In some embodiments, the tumor is a c-Met overexpressing tumor. In some embodiments, the tumor is a solid tumor. In some embodiments, the tumor is a non-solid tumor. In some embodiments, the tumor is a brain malignancy, head and neck cancer, lung cancer, esophageal cancer, pharyngeal cancer, nasal cancer, tongue cancer, oral cancer, thyroid cancer, skin cancer, bone cancer, soft tissue sarcoma, myeloma, gastric cancer, gastroesophageal junction adenocarcinoma, breast cancer, liver cancer, kidney cancer, pancreatic cancer, splenic cancer, lymphoma, thymic cancer, bladder cancer, vaginal cancer, testicular cancer, uterine cancer, cervical cancer, colorectal cancer, anal cancer, papillary cancer, prostate cancer, ovarian cancer, epithelial cell cancer, or hematological tumor. In some embodiments, the lung cancer is non-small cell lung cancer. In some embodiments, the brain malignancy is glioblastoma.
[0125] The present disclosure further provides the following specific embodiments, which are not intended to limit the scope of the invention.
[0126] Embodiment 1. An isolated antibody or antigen-binding fragment thereof that binds to c-Met and comprises at least one single variable domain, wherein the single variable domain has the following complementarity determining regions: a) CDR1 comprising the amino acid sequence set forth in SEQ ID NO: 5, 8, 11, 14, 17, or 20; b) a CDR2 comprising the amino acid sequence set forth in SEQ ID NO: 6, 9, 12, 15, 18, or 21; and c) CDR3 comprising the amino acid sequence set forth in SEQ ID NO: 7, 10, 13, 16, 19, or 22 An antibody or an antigen-binding fragment thereof comprising:
[0127] Embodiment 2. The single variable domain comprises: a) CDR1 comprising the amino acid sequence set forth in SEQ ID NO:5, CDR2 comprising the amino acid sequence set forth in SEQ ID NO:6, and CDR3 comprising the amino acid sequence set forth in SEQ ID NO:7; b) CDR1 comprising the amino acid sequence set forth in SEQ ID NO:8, CDR2 comprising the amino acid sequence set forth in SEQ ID NO:9, and CDR3 comprising the amino acid sequence set forth in SEQ ID NO:10; c) CDR1 comprising the amino acid sequence set forth in SEQ ID NO: 11, CDR2 comprising the amino acid sequence set forth in SEQ ID NO: 12, and CDR3 comprising the amino acid sequence set forth in SEQ ID NO: 13; d) CDR1 comprising the amino acid sequence set forth in SEQ ID NO: 14, CDR2 comprising the amino acid sequence set forth in SEQ ID NO: 15, and CDR3 comprising the amino acid sequence set forth in SEQ ID NO: 16; e) a CDR1 comprising the amino acid sequence set forth in SEQ ID NO: 17, a CDR2 comprising the amino acid sequence set forth in SEQ ID NO: 18, and a CDR3 comprising the amino acid sequence set forth in SEQ ID NO: 19; or f) CDR1 comprising the amino acid sequence set forth in SEQ ID NO: 20, CDR2 comprising the amino acid sequence set forth in SEQ ID NO: 21, and CDR3 comprising the amino acid sequence set forth in SEQ ID NO: 22. 2. The isolated antibody or antigen-binding fragment thereof of embodiment 1, comprising:
[0128] Embodiment 3. The isolated antibody or antigen-binding fragment thereof of embodiment 2, wherein the single variable domain comprises an amino acid sequence having at least 85% identity to the amino acid sequence set forth in SEQ ID NO: 24, 26, 28, 30, 32, or 34.
[0129] Embodiment 4. The isolated antibody or antigen-binding fragment thereof of embodiment 3, wherein the single variable domain comprises an amino acid sequence set forth in SEQ ID NO: 24, 26, 28, 30, 32, or 34.
[0130] Embodiment 5. The single variable domain is V H 5. The isolated antibody or antigen-binding fragment thereof according to any one of embodiments 1 to 4, wherein said antibody or antigen-binding fragment is H.
[0131] Embodiment 6. The isolated antibody or antigen-binding fragment thereof of any one of embodiments 1 to 5, which is chimeric or humanized.
[0132] Embodiment 7. The isolated antibody or antigen-binding fragment thereof according to any one of embodiments 1 to 6, comprising an Fc of human IgG, preferably an Fc of human IgG1, IgG2, IgG3, or IgG4.
[0133] Embodiment 8. An isolated antibody or antigen-binding fragment thereof described in any one of embodiments 1 to 7, comprising the amino acid sequence set forth in SEQ ID NO: 37, 39, 41, 43, 45, or 47.
[0134] Embodiment 9. An isolated antibody or antigen-binding fragment thereof according to any one of embodiments 1 to 8, which may comprise one or several of the following properties and characteristics, either alone or in combination:
[0135] Embodiment 10. Binding to human c-Met or / and monkey c-Met.
[0136] Embodiment 11. Blocking the binding of HGF or its β chain to c-Met.
[0137] Embodiment 12. Inhibiting c-Met phosphorylation caused by HGF stimulation.
[0138] Embodiment 13. Exerting an ADCC effect against tumor cells.
[0139] Embodiment 14. A fusion protein comprising the antibody or antigen-binding fragment thereof according to any one of embodiments 1 to 9.
[0140] Embodiment 15. A pharmaceutical composition comprising the antibody or antigen-binding fragment thereof described in any one of embodiments 1 to 9, or the fusion protein described in embodiment 10, and a pharma- ceutical acceptable carrier.
[0141] Embodiment 16. An isolated nucleic acid encoding the antibody or antigen-binding fragment thereof according to any one of embodiments 1 to 9, or the fusion protein according to embodiment 10.
[0142] Embodiment 17. A vector comprising the isolated nucleic acid of embodiment 12.
[0143] Embodiment 18. A host cell comprising the nucleic acid of embodiment 12 or the vector of embodiment 13.
[0144] Embodiment 19. A method for preparing an isolated antibody or antigen-binding fragment thereof described in any one of embodiments 1 to 9, comprising culturing a host cell described in embodiment 14 and isolating the expressed antibody or antigen-binding fragment thereof, wherein the vector is an expression vector.
[0145] Embodiment 20. Use of the isolated antibody or antigen-binding fragment thereof according to any one of embodiments 1 to 9 for the preparation of a medicament for treating a subject having a tumor.
[0146] Embodiment 21. Use of the fusion protein of embodiment 10 for the preparation of a medicament for treating a subject having a tumor.
[0147] Embodiment 22. Use of the pharmaceutical composition of embodiment 11 for preparing a medicament for treating a subject having a tumor.
[0148] Embodiment 23. The use according to any one of embodiments 16 to 18, wherein the tumor is a brain malignancy, head and neck cancer, lung cancer, esophageal cancer, pharyngeal cancer, nasal cancer, tongue cancer, oral cancer, thyroid cancer, skin cancer, bone cancer, soft tissue sarcoma, myeloma, gastric cancer, gastroesophageal junction adenocarcinoma, breast cancer, liver cancer, kidney cancer, pancreatic cancer, splenic cancer, lymphoma, thymic cancer, bladder cancer, vaginal cancer, testicular cancer, uterine cancer, cervical cancer, colorectal cancer, anal cancer, papillary cancer, prostate cancer, ovarian cancer, epithelial cell carcinoma, or blood tumor.
[0149] Embodiment 24. A method for detecting or measuring c-Met in a sample, comprising contacting the sample with an antibody or antigen-binding fragment thereof of any one of embodiments 1 to 9, and detecting or measuring the binding complex.
[0150] Embodiment 25. A method for inhibiting, reducing or blocking c-Met signaling in a cell, comprising administering to the cell an effective amount of the antibody or antigen-binding fragment thereof described in any one of Embodiments 1 to 9, the fusion protein described in Embodiment 10, or the pharmaceutical composition described in Embodiment 11.
[0151] Embodiment 26. A method for inhibiting the proliferation of or killing tumor cells, comprising administering to the tumor cells an effective amount of the antibody or antigen-binding fragment thereof described in any one of Embodiments 1 to 9, the fusion protein described in Embodiment 10, or the pharmaceutical composition described in Embodiment 11.
[0152] Embodiment 27. A method for treating a subject having a tumor, comprising administering to the subject a therapeutically effective amount of the antibody or antigen-binding fragment thereof described in any one of Embodiments 1 to 9, the fusion protein described in Embodiment 10, or the pharmaceutical composition described in Embodiment 11.
[0153] Embodiment 28. The method of embodiment 22 or 23, wherein the tumor is a brain malignancy, head and neck cancer, lung cancer, esophageal cancer, pharyngeal cancer, nasal cancer, tongue cancer, oral cancer, thyroid cancer, skin cancer, bone cancer, soft tissue sarcoma, myeloma, gastric cancer, gastroesophageal junction adenocarcinoma, breast cancer, liver cancer, kidney cancer, pancreatic cancer, splenic cancer, lymphoma, thymic cancer, bladder cancer, vaginal cancer, testicular cancer, uterine cancer, cervical cancer, colorectal cancer, anal cancer, papillary cancer, prostate cancer, ovarian cancer, epithelial cell carcinoma, or blood tumor.
[0154] Although the above invention has been described in some detail by providing illustrations and examples for clarity of understanding, it will be apparent to those skilled in the art in light of the teachings of the present disclosure that certain changes and modifications can be made to the present disclosure without departing from the spirit or scope of the appended claims. The following examples are provided for illustrative purposes only and are not intended to be limiting. Those skilled in the art will readily identify a variety of non-critical parameters that can be changed or modified to obtain substantially similar results. EXAMPLES
[0155] Anti-c-Met V H Construction of H phage display library 1.1 Immunization of animals Recombinant human c-Met-Fc fusion protein (SinoBiological Co., Ltd., product catalogue number 10692-H02H) was emulsified with Freund's complete adjuvant at a 1:1 volume ratio. Camels were first immunized by subcutaneous multiple injections, followed by booster immunizations at 2-week intervals with recombinant human c-Met-Fc fusion protein emulsified with Freund's incomplete adjuvant at a 1:1 volume ratio. Serum was collected after the fourth or fifth immunization and assayed for anti-human c-Met antibody titers. After multiple immunizations, peripheral blood was collected from the camels to isolate peripheral blood mononuclear cells (PBMCs).
[0156] 1.2 RNA extraction Total RNA was extracted from PBMCs (from 1.1) using TRIzol™ reagent. The quality of the extracted total RNA was assessed by 1% agarose gel electrophoresis. Quantification was performed by measuring the absorbance at 260 nm and 280 nm. OD 260nm / OD 280nm The ratio should be between 1.8 and 2.0.
[0157] 1.3 V H H Amplification Total RNA was reverse transcribed into cDNA using a cDNA synthesis kit, PrimeScript™ II 1st Strand cDNA Synthesis Kit (TAKARA, product catalog number 6210A) according to the instructions. H H) sequence was specifically amplified by nested PCR as follows: A first round of PCR amplification was performed using primers Call001 (SEQ ID NO: 1) and Call002 (SEQ ID NO: 2) with cDNA as a template. The DNA product obtained by amplification in the form of a short fragment was purified using a gel recovery kit (QIAGEN, product catalog number 28706). A second round of PCR amplification was performed using the product of the first round of PCR as a template with primers V-Back (SEQ ID NO: 3) and V-Fwd (SEQ ID NO: 4). The DNA product obtained by amplification was V H The fragment encoding H was then purified using a gel recovery kit (QIAGEN, product catalogue no. 28706). Call001 (SEQ ID NO: 1): GTCCTGGCTGCTCTTCTACAAGG Call002 (SEQ ID NO: 2): GGTACGTGCTGTTGAACTGTTCC V-Back (SEQ ID NO: 3): GATGTGCAGCTGCAGGAGTCTGGRGGAGG V-Fwd (SEQ ID NO: 4): CTAGTGCGGCCGCTGAGGAGACGGTGACCTGGGT
[0158] 1.4 V H Construction of H phage library The amplified V HThe H-encoding fragment was digested with PstI / NotI endonuclease and inserted into the phagemid vector pMECS (NTCC Plasmid Vector, Strain, Cell and Gene Collection, product catalog number pMECS) to construct a recombinant vector, which was then electrotransfected into Escherichia coli TG1 (Lucigen, product catalog number 60502-1). A small aliquot of the transformed bacteria was diluted and then applied to a selection plate containing 100 μg / mL ampicillin. The library volume was calculated by colony counting, and 100 random clones were picked and sequenced to assess the quality of the library. The remaining bacterial liquid was applied to a selection plate containing 100 μg / mL ampicillin. The lawn of bacterial colonies was scraped off the plate, glycerol was added, and frozen and stored at -80°C as library stocks. The library stocks were amplified to logarithmic growth phase. Amplification of the library was performed by adding M13KO7 helper phage (New England Biolabs, product catalog number N0315S) and shaking at 200 rpm at 28°C overnight. The bacterial solution was centrifuged and the supernatant was collected. 1 / 4 of the supernatant volume of PEG6000 / NaCl solution (20% PEG6000 (w / v), 2.5M NaCl) was added. The mixture was incubated on ice for 1-2 hours to allow phages to precipitate. The precipitated phages were collected by centrifugation and resuspended in PBS, followed by the addition of 20% glycerol. The suspension was then transferred to a 500-well plate for 10 min at 37°C. H The resulting phage display library was stored at -80°C. EXAMPLES
[0159] Anti-human c-Met V H Screening for H 2.1 Panning V HThe H phage display library was subjected to solid-phase panning. Recombinant c-Met-Avitage™ (ACRO, product catalog number MET-H82E1) was immobilized on a high-adsorption microplate. After blocking, the phages obtained in 1.4 were added to the well plate, and the plate was incubated at 37°C for 1-2 hours. The plate was washed 10 times with phosphate-buffered saline containing Tween (PBST) to remove non-specifically bound phages. After washing with PBS, the bound phages were eluted with trypsin. The enzyme was neutralized with 4-(2-aminoethyl)benzenesulfonyl fluoride hydrochloride (AEBSF), and the eluted phages were used to infect E. coli TG1. After amplification, another round of library panning was performed. After 2-3 rounds of panning and enrichment, the recovered phages were used to infect E. coli TG1 in the logarithmic growth phase. The bacteria were spread onto selection plates containing 20% (w / v) glucose and 100 μg / mL ampicillin. Individual clones were picked and cultured. Expression was induced with isopropyl-β-D-thiogalactoside (IPTG) and the supernatants were collected.
[0160] 2.2 Identification of positive clones The collected clones were subjected to positive identification by indirect ELISA for human c-Met-His (SinoBiological, product catalogue number 10692-H08H). Human c-Met-His or control protein human Fc protein (ACRO, product catalogue number FCC-H5214) was coated on a high-adsorption microplate, followed by blocking with blocking buffer. The supernatant prepared in 2.1 was added, and the plate was incubated at 37°C for 1 hour. After washing the plate, HRP-conjugated anti-HA tag secondary antibody (GenScript, product catalogue number A01296) was added. The plate was incubated at 37°C for 0.5 hours, washed five times, and developed by adding a chromogenic substrate. The light absorption signal value was measured at a wavelength of 450 nm and a reference wavelength of 650 nm. Positive clones that only bound to human c-Met-His with a relatively high signal value were selected for storage and sequenced.
[0161] Positive clones 1B-1B2, 1B-3B11, 1B-1C7, 1B-1B6, 1B-1A8 and 3B-1C7 were obtained by screening. H H has the nucleotide sequence set forth in SEQ ID NO:23 and the amino acid sequence set forth in SEQ ID NO:24; V H H has the nucleotide sequence set forth in SEQ ID NO:25 and the amino acid sequence set forth in SEQ ID NO:26; V H H has the nucleotide sequence set forth in SEQ ID NO:27 and the amino acid sequence set forth in SEQ ID NO:28; V H H has the nucleotide sequence set forth in SEQ ID NO:29 and the amino acid sequence set forth in SEQ ID NO:30; V H H has the nucleotide sequence set forth in SEQ ID NO:31 and the amino acid sequence set forth in SEQ ID NO:32; V H H is shown to have the nucleotide sequence set forth in SEQ ID NO:33 and the amino acid sequence set forth in SEQ ID NO:34. EXAMPLES
[0162] Anti-human c-Met V H Preparation of H-Fc chimeric antibody 3.1 V H Preparation of H-Fc chimeric antibody V of positive clones obtained by screening H The H sequence was linked to a human Fc region to form the V H A H-Fc chimeric antibody was constructed. Specifically, the V H The VH sequence was inserted into the pCDNA3.1 eukaryotic expression vector containing the human IgG1 Fc region and expressed using the Expifectamine™ CHO Transfection Kit transient expression system (Thermo Fisher Scientific, product catalog number A29129). H H-Fc chimeric antibody was expressed.
[0163] Sequence analysis shows that the full length of 1B-3B11-Fc has the amino acid sequence set forth in SEQ ID NO:37 and the nucleotide sequence set forth in SEQ ID NO:36, the full length of 1B-1B6-Fc has the amino acid sequence set forth in SEQ ID NO:39 and the nucleotide sequence set forth in SEQ ID NO:38, the full length of 1B-1C7-Fc has the amino acid sequence set forth in SEQ ID NO:41 and the nucleotide sequence set forth in SEQ ID NO:40, the full length of 1B-1A8-Fc has the amino acid sequence set forth in SEQ ID NO:43 and the nucleotide sequence set forth in SEQ ID NO:42, the full length of 1B-1B2-Fc has the amino acid sequence set forth in SEQ ID NO:45 and the nucleotide sequence set forth in SEQ ID NO:44, and the full length of 3B-1C7-Fc has the amino acid sequence set forth in SEQ ID NO:47 and the nucleotide sequence set forth in SEQ ID NO:46.
[0164] 3.2 V by surface plasmon resonance H Measurement of affinity of H-Fc chimeric antibodies to human c-Met and cynomolgus monkey c-Met Anti-human c-Met V H The H-Fc chimeric antibodies were tested for affinity using a biomolecular interaction analysis system (GE, Biacore T200). Anti-hIgG(Fc) antibody (GE, product catalog number BR-1008-39) was amino-coupled to a CM5 sensor chip. Anti-human c-Met V HH-Fc chimeric antibodies were diluted to 1 μg / mL in running buffer (137 mM NaCl, 2.7 mM KCl, 10 mM Na2HPO4·12H2O, 1.8 mM KH2PO4, 0.05% surfactant P-20 (w / v), pH 7.4) and captured by passing the diluted solution through the experimental channel at a flow rate of 30 μL / min. Human c-Met-His (SinoBiological, product catalog number 10692-H08H) or cynomolgus c-Met-His (SinoBiological, catalog number 90304-C08H) were diluted to 100 nM, 50 nM, 25 nM, 12.5 nM, 6.25 nM, and 3.125 nM in running buffer and binding was performed for 200 seconds by passing the diluted solution through the experimental channel at a flow rate of 50 μL / min. The dissociation was then allowed to proceed for 800 seconds by stopping the sample injection. Data signals were collected in real time by BiaControl Software 2.0 and analyzed by BiaEvaluation Software 2.0. The binding rate constant K was calculated by fitting using the Langmuir 1:1 model. a (1 / Ms), dissociation rate constant K d (1 / s) and the equilibrium dissociation constant K D (M) was calculated. The results are shown in Table 1. 1B-1B2-Fc, 1B-3B11-Fc, 1B-1C7-Fc, 1B-1B6-Fc, 1B-1A8-Fc and 3B-1C7-Fc all have relatively high affinity for human c-Met protein and all have cross-reactivity with cynomolgus monkey c-Met protein.
[0165] [Table 4] EXAMPLES
[0166] Anti-human c-Met V H Binding of H-Fc chimeric antibodies to native cell lines expressing c-Met 4.1 Anti-human c-Met V H Flow cytometry assay for binding of H-Fc chimeric antibodies to cells Anti-human c-Met V H The binding of H-Fc chimeric antibody to target cells with different c-Met expression levels was detected by flow cytometry. H1993 cells (Beina Bio, product catalog number BNCC342186) are human lung adenocarcinoma cell lines with high c-Met expression levels, MKN45 cells (Nanjing Cobioer Biosciences, product catalog number CBP60541) are human gastric cancer cell lines with moderate c-Met expression levels, and KP4 cells (Nanjing Cobioer Biosciences, product catalog number CBP60541) are human pancreatic cancer cell lines with low c-Met expression levels. 2×10 5 Target cells were incubated with serially diluted anti-human c-Met V H After incubation with H-Fc chimeric antibody (seven concentrations were serially diluted 5-fold from an initial concentration of 100 nM) on ice for 1 hour, the cells were washed. PE-labeled anti-human IgG Fc antibody (Jackson ImmunoResearch, product catalog number 109-116-170) was added, and the mixture was incubated on ice for 0.5 hours. The cells were washed and then examined using a flow cytometer (Thermo Fisher Scientific, Attune NXT). The results are shown in Figure 1A-1C and Table 2. 1B-1B2-Fc, 1B-3B11-Fc, 1B-1C7-Fc, 1B-1B6-Fc, 1B-1A8-Fc, and 3B-1C7-Fc all have relatively high binding ability to target cells with different c-Met expression levels.
[0167] [Table 5]
[0168] 4.2 Anti-human c-Met V H Flow cytometry assay for binding of H-Fc chimeric antibodies to cells expressing macaque c-Met Anti-human c-Met V HThe binding of H-Fc chimeric antibody to macaque epithelial cell 4MBr-5 (Shanghai Qingqi Biotechnology Development Co., Ltd., product catalog number BFN60807362) was detected by flow cytometry by referring to the method in 4.1. The results are shown in Figure 1D and Table 3. 1B-1B2-Fc, 1B-3B11-Fc, 1B-1C7-Fc, 1B-1B6-Fc, 1B-1A8-Fc, and 3B-1C7-Fc can all effectively target and bind to the macaque epithelial cell 4MBr-5 expressing c-Met.
[0169] [Table 6] EXAMPLES
[0170] Anti-human c-Met V H Blockade of receptor / ligand binding by H-Fc chimeric antibodies and antibody epitope competition analysis 5.1 Anti-human c-Met V H Blockade of HGF and HGFβ binding to c-Met receptor by H-Fc chimeric antibody Anti-human c-Met V H Whether the H-Fc chimeric antibody can block the binding of hepatocyte growth factor (HGF) to the c-Met receptor was analyzed by competitive ELISA. Specifically, 2 μg / mL of human c-Met-His protein (SinoBiological Co., Ltd., product catalog number 10692-H08H) was coated on a high-adsorption microplate, which was then blocked with 3% (w / v) BSA blocking buffer and washed, and then 80 ng / mL of biotin-conjugated HGF (SinoBiological Co., Ltd., product catalog number 10463-HNAS) and anti-human c-Met V were added to the plate. HH-Fc chimeric antibody (seven concentrations were obtained by serially diluting five-fold from an initial concentration of 100 nM) was added and incubated at 25°C for 2 hours. After washing the plate, HRP-conjugated streptavidin (eBioscience, product catalog number 18-4100-51) was added. The plate was incubated at 25°C for 1 hour, washed five times, and TMB substrate solution (TIANGEN, product catalog number PA107) was added at 100 μL / well to develop color. Absorbance signal values were measured at a wavelength of 450 nm and a reference wavelength of 650 nm. The curve (Figure 2A) was fitted to obtain the IC 50 The values (Table 4) were calculated.
[0171] The same method was used to detect anti-human c-Met V H We analyzed whether the H-Fc chimeric antibody can block the binding of the HGF β chain (HGFβ, NP_000592.3, Val495-Ser728) to the c-Met receptor. HGFβ has the amino acid sequence set forth in SEQ ID NO: 35. Based on this result, a curve (FIG. 2B) was fitted to obtain the IC 50 Values were calculated (Table 4).
[0172] According to these results, 1B-3B11-Fc, 1B-1B2-Fc, 1B-1C7-Fc, 1B-1B6-Fc, 1B-1A8-Fc, and 3B-1C7-Fc are all capable of blocking the binding of HGF to the c-Met receptor, 1B-3B11-Fc, 1B-1C7-Fc, 1B-1B6-Fc, and 1B-1A8-Fc are capable of blocking the binding of HGFβ to the c-Met receptor, and 1B-1B2-Fc and 3B-1C7-Fc are unable to block the binding of HGFβ to the c-Met receptor.
[0173] [Table 7]
[0174] 5.2 Anti-human c-Met V by surface plasmon resonance H Examination of the competitive relationship between different H-Fc clones The epitope competition analysis was performed using a biomolecular interaction system (Fortebio, product catalog number Octet RED96). The Anti-Penta-HIS (HIS1K) sensor (Fortebio, product catalog number 18-5120) was used, and c-Met-His protein (SinoBiological, product catalog number 10692-H08H) was diluted to about 5 μg / mL using running buffer. The sensor was immersed in the diluted antigen sample. The immobilization height was controlled to about 1 nm by adjusting the binding time. The antigen sample was then allowed to interact with the first antibody A and the second antibody B in sequence, and the B antibody binding signal was detected to determine whether the two antibodies recognize the same epitope. The results are shown in Table 5-1 and Table 5-2. The criteria were: a value above 60% indicates no competition between the two antibodies, a value between 20% and 60% indicates partial competition between the two antibodies (possible crossover at the epitope site), and a value below 20% indicates complete competition between the two antibodies. Data were considered valid when the autoreactive signal (gray area) was below 20%.
[0175] As can be seen from the data in Table 5-1, the two antibodies 1B-3B11-Fc and 1B-1A8-Fc competed completely, and 1B-3B11-Fc and 1B-1A8-Fc had no obvious competitive relationship with the other three candidate antibodies, each of which belonged to a different epitope. Thus, antibodies 1B-3B11-Fc and 1B-1B2-Fc, 1B-3B11-Fc and 1B-1C7-Fc, 1B-3B11-Fc and 1B-1B6-Fc, 1B-1A8-Fc and 1B-1B2-Fc, 1B-1A8-Fc and 1B-1C7-Fc, 1B-1A8-Fc and 1B-1B6-Fc, 1B-1B2-Fc and 1B-1C7-Fc, 1B-1B2-Fc and 1B-1B6-Fc, and 1B-1C7-Fc and 1B-1B6-Fc can simultaneously bind to different epitopes of the c-Met antigen.
[0176] As can be seen from the data in Table 5-2, the two antibodies 3B-1C7-Fc and 1B-1B2-Fc competed completely. Therefore, combined with the data from Table 5-1, it can be seen that the antibodies 1B-1A8-Fc and 3B-1C7-Fc, 3B-1C7-Fc and 1B-1C7-Fc, and 3B-1C7-Fc and 1B-1B6-Fc can simultaneously bind to different epitopes of the c-Met antigen.
[0177] [Table 8] EXAMPLES
[0178] Anti-human c-Met V H Inhibition of c-Met phosphorylation in H441 cells by H-Fc chimeric antibodies The inhibitory effect of the antibodies on c-Met phosphorylation caused by HGF stimulation in H441 cells (Beina Bio, product catalog number BNCC292357) was detected using the phospho-c-Met (Tyr1234 / 1235) AlphaLISA SureFire Ultra Assay Kit (PerkinElmer, product catalog number ALSU-PC-MET-A500). H441 cells were harvested according to the supplier's instructions and seeded in 96-well plates at 100 μL / well and 10,000 cells / well. After 6-16 hours of incubation, the cells were starved overnight in serum-free medium. The supernatant was discarded and incubated with anti-human c-Met V HH-Fc chimeric antibody (10-fold serially diluted from an initial concentration of 1000 nM to 7 concentrations) was added at 45 μL / well, the mixture was incubated for 30 min, and 5 μL HGF was added to stimulate for 15 min. The supernatant was discarded, and 100 μL of freshly prepared 1× lysis buffer was added. After 10 min of incubation, the plate was read using the AlphaLISA module. The results are shown in FIG. 3 and Table 6. 1B-1B2-Fc, 1B-3B11-Fc, 1B-1C7-Fc, 1B-1B6-Fc, 1B-1A8-Fc, and 3B-1C7-Fc can all effectively inhibit c-Met downstream phosphorylation in H441 cells caused by HGF stimulation.
[0179] [Table 9] EXAMPLES
[0180] Anti-human c-Met V H Inhibition of KP4 cell proliferation by H-Fc chimeric antibodies The inhibitory effect of the antibody on the proliferation of KP4 cells was detected using the Cell Counting Kit 8 (DOJINDO Laboratories, Lot. SH797) method. Specifically, KP4 cells were added to a 96-well cell culture plate at 1000 cells / well and incubated at 37°C in a 5% CO2 carbon dioxide cell incubator. After the cells were allowed to adhere to the wall, anti-human c-Met V was used. H H-Fc chimeric antibody (2-fold serial dilution from initial concentration 900 nM to 7 concentrations) was added to the cells. After 120 h of incubation, 10 μL of CCK-8 solution was added to each well. After 1 h of incubation, the absorbance at 450 nm was measured using a microplate reader. The results are shown in FIG. 4 and Table 7. 1B-3B11-Fc, 1B-1C7-Fc, 1B-1B6-Fc, 1B-1A8-Fc, and 3B-1C7-Fc can all effectively inhibit the proliferation of KP4 cells.
[0181] The formula for calculating cell viability is as follows: Cell viability = [(As-Ab) / (Ac-Ab)]×100% As = absorbance of experimental wells (absorbance of wells containing cells, medium, CCK-8, and test antibody); Ab=absorbance of blank wells (absorbance of wells containing medium and CCK-8); Ac=absorbance of control wells (absorbance of wells containing cells, medium and CCK-8); Growth inhibition rate = 100% - cell viability
[0182] [Table 10]
Claims
1. 1. An isolated antibody or antigen-binding fragment thereof, which binds to c-Met and comprises at least one single variable domain, wherein the single variable domain has the following complementarity determining regions: (a) CDR1 comprising the amino acid sequence set forth in SEQ ID NO: 11, 8, 5, 14, 17 or 20; (b) a CDR2 comprising the amino acid sequence set forth in SEQ ID NO: 12, 9, 6, 15, 18 or 21, and (c) a CDR3 comprising the amino acid sequence set forth in SEQ ID NO: 13, 10, 7, 16, 19 or 22 An antibody or an antigen-binding fragment thereof comprising:
2. The single variable domain comprises (a) CDR1 comprising the amino acid sequence set forth in SEQ ID NO: 11, CDR2 comprising the amino acid sequence set forth in SEQ ID NO: 12, and CDR3 comprising the amino acid sequence set forth in SEQ ID NO: 13; (b) CDR1 comprising the amino acid sequence set forth in SEQ ID NO:8, CDR2 comprising the amino acid sequence set forth in SEQ ID NO:9, and CDR3 comprising the amino acid sequence set forth in SEQ ID NO:10; (c) CDR1 comprising the amino acid sequence set forth in SEQ ID NO:5, CDR2 comprising the amino acid sequence set forth in SEQ ID NO:6, and CDR3 comprising the amino acid sequence set forth in SEQ ID NO:7; (d) CDR1 comprising the amino acid sequence set forth in SEQ ID NO: 14, CDR2 comprising the amino acid sequence set forth in SEQ ID NO: 15, and CDR3 comprising the amino acid sequence set forth in SEQ ID NO: 16; (e) a CDR1 comprising the amino acid sequence set forth in SEQ ID NO: 17, a CDR2 comprising the amino acid sequence set forth in SEQ ID NO: 18, and a CDR3 comprising the amino acid sequence set forth in SEQ ID NO: 19; or (f) CDR1 comprising the amino acid sequence set forth in SEQ ID NO: 20, CDR2 comprising the amino acid sequence set forth in SEQ ID NO: 21, and CDR3 comprising the amino acid sequence set forth in SEQ ID NO:
22.
2. The isolated antibody or antigen-binding fragment thereof of claim 1, comprising:
3. the single variable domain comprises an amino acid sequence having at least 85% identity to the amino acid sequence set forth in SEQ ID NO: 24, 26, 28, 30, 32, or 34; or The single variable domain comprises an amino acid sequence set forth in SEQ ID NO: 24, 26, 28, 30, 32, or 34; 3. An isolated antibody or antigen-binding fragment thereof according to claim 2.
4. The single variable domain is V H 4. The isolated antibody or antigen-binding fragment thereof of any one of claims 1 to 3, wherein H is H, and optionally the antibody or antigen-binding fragment thereof is chimeric or humanized.
5. 5. The isolated antibody or antigen-binding fragment thereof of any one of claims 1 to 4, comprising a human IgG Fc, preferably a human IgG1, IgG2, IgG3, or IgG4 Fc, and optionally comprising the amino acid sequence set forth in SEQ ID NO: 37, 39, 41, 43, 45, or 47.
6. The following characteristics and features: (a) binding to human c-Met and / or monkey c-Met; (b) blocking the binding of HGF or its β chain to c-Met; (c) inhibiting c-Met phosphorylation induced by HGF stimulation; (d) exerting an ADCC effect on tumor cells 6. The isolated antibody or antigen-binding fragment thereof according to any one of claims 1 to 5, which may comprise one or several of the following, alone or in combination:
7. A fusion protein comprising an antibody or an antigen-binding fragment thereof according to any one of claims 1 to 6.
8. A pharmaceutical composition comprising an antibody or an antigen-binding fragment thereof described in any one of claims 1 to 6, or a fusion protein described in claim 7, and a pharma- ceutically acceptable carrier.
9. An isolated nucleic acid encoding an antibody or antigen-binding fragment thereof according to any one of claims 1 to 6 or a fusion protein according to claim 7.
10. A vector comprising the isolated nucleic acid of claim 9.
11. A host cell comprising a nucleic acid according to claim 9 or a vector according to claim 10.
12. 12. A method for preparing an isolated antibody or antigen-binding fragment thereof according to any one of claims 1 to 6, comprising culturing a host cell according to claim 11 and isolating the expressed antibody or antigen-binding fragment thereof, wherein the vector is an expression vector.
13. 9. Use of the isolated antibody or antigen-binding fragment thereof according to any one of claims 1 to 6, the fusion protein according to claim 7, or the pharmaceutical composition according to claim 8, for the preparation of a medicament for treating a subject having a tumor, preferably wherein the tumor is brain malignancy, head and neck cancer, lung cancer, esophageal cancer, pharyngeal cancer, nasal cancer, tongue cancer, oral cancer, thyroid cancer, skin cancer, bone cancer, soft tissue sarcoma, myeloma, gastric cancer, gastroesophageal junction adenocarcinoma, breast cancer, liver cancer, kidney cancer, pancreatic cancer, splenic cancer, lymphoma, thymic cancer, bladder cancer, vaginal cancer, testicular cancer, uterine cancer, cervical cancer, colorectal cancer, anal cancer, papillary cancer, prostate cancer, ovarian cancer, epithelial cell cancer, or blood tumor.
14. 10. A method for detecting or measuring c-Met in a sample, comprising the steps of contacting the sample with an antibody or antigen-binding fragment thereof according to any one of claims 1 to 6, and detecting or measuring the binding complex.
15. 9. A method for inhibiting, reducing or blocking c-Met signaling in a cell, comprising administering to the cell an effective amount of an antibody or antigen-binding fragment thereof described in any one of claims 1 to 6, a fusion protein described in claim 7, or a pharmaceutical composition described in claim 8.
16. A method for inhibiting the proliferation of or killing tumor cells, comprising administering to the tumor cells an effective amount of an antibody or antigen-binding fragment thereof described in any one of claims 1 to 6, a fusion protein described in claim 7, or a pharmaceutical composition described in claim 8.
17. A method for treating a subject having a tumor, comprising administering to the subject a therapeutically effective amount of an antibody or antigen-binding fragment thereof described in any one of claims 1 to 6, a fusion protein described in claim 7, or a pharmaceutical composition described in claim 8.
18. 18. The method of claim 16 or 17, wherein the tumor is a brain malignancy, head and neck cancer, lung cancer, esophageal cancer, pharyngeal cancer, nasal cancer, tongue cancer, oral cancer, thyroid cancer, skin cancer, bone cancer, soft tissue sarcoma, myeloma, gastric cancer, gastroesophageal junction adenocarcinoma, breast cancer, liver cancer, kidney cancer, pancreatic cancer, splenic cancer, lymphoma, thymic cancer, bladder cancer, vaginal cancer, testicular cancer, uterine cancer, cervical cancer, colorectal cancer, anal cancer, papillary cancer, prostate cancer, ovarian cancer, epithelial cell cancer, or blood tumor.
Citation Information
Patent Citations
cMet-related biological substances
JP2015501135A
